Abstract
The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 284-296 |
| Number of pages | 13 |
| Journal | Genetic testing and molecular biomarkers |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2019 |
Keywords
- cancer
- circulating DNA
- circulating tumor cells
- extracellular vesicles
- liquid biopsy
ASJC Scopus subject areas
- Genetics(clinical)